Treatment of colorectal cancer

More than 40,000 individuals are affected by colorectal cancer per year, making this one of the commonest cancers in France. When it is detected at an early stage, it can be cured in 9 cases out of 10. Each year Gustave Roussy sees more than 3,000 patients with the condition. The Digestive Diseases Committee is responsible for the management of these patients.

Description

The Gustave Roussy Medical Oncology Department is one of the largest in France with a team of more than 430 personnel. It covers a very wide clinical spectrum consisting of all cancer specialties as well as rare cancers.

Double strand break repair and Genome Integrity Team

This team belongs to the UMR 9019 Genome Integrity and Cancers.

Traitement des sarcomes et tumeurs complexes

La chirurgie est la pierre angulaire du traitement curatif des sarcomes, quand celle-ci est possible et que la maladie n'est pas métastatique. Elle peut être associée à de la radiothérapie et/ou à de la chimiothérapie.

Treatment of sarcomas and complex tumours

Gustave Roussy treats patients with soft tissue and bone sarcomas, desmoid tumours, gastrointestinal stromal tumours (GIST) and other complex tumours (chordomas and PEComas).
Sarcomas are tumours which arise in connective tissue (mesenchyme). There are a number of types of mesenchymal tumours whose consequences and severity vary greatly depending on:

Lab members

• Murat SAPARBAEV, Research Director, DR1, CNRS;
• Alexandre A. ISHCHENKO, Research Director, DR2, CNRS;
• Regina GROISMAN, CRCN, INSERM;
• Sophie GAD-LAPITEAU, Professor, EPHE ;
• Sophie COUVE, Assistant professor, EPHE ;
• Flore RENAUD-PAITRA, Assistant professor, EPHE ;
• Sophie FERLICOT, PU-PH, clinicien, Université Paris-Saclay ;
• Dominique BLUTEAU, Assistant professor, EPHE ;
• Kévin BOQUET, technician, EPHE;
• Victoria POILLERAT, PhD student, EPHE;